KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $1.5 million.

  • Halozyme Therapeutics' Treasury Shares rose 880.27% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 million, marking a year-over-year increase of 880.27%. This contributed to the annual value of $1.5 million for FY2025, which is 880.27% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Treasury Shares is $1.5 million, which was up 880.27% from $1.4 million recorded in Q4 2024.
  • Over the past 5 years, Halozyme Therapeutics' Treasury Shares peaked at $19.1 million during Q2 2024, and registered a low of $1.0 million during Q2 2021.
  • Moreover, its 5-year median value for Treasury Shares was $4.0 million (2021), whereas its average is $5.2 million.
  • In the last 5 years, Halozyme Therapeutics' Treasury Shares soared by 107493.18% in 2021 and then plummeted by 7468.14% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Treasury Shares (Quarter) stood at $3.9 million in 2021, then rose by 15.38% to $4.5 million in 2022, then tumbled by 74.68% to $1.1 million in 2023, then grew by 22.77% to $1.4 million in 2024, then rose by 8.8% to $1.5 million in 2025.
  • Its Treasury Shares stands at $1.5 million for Q4 2025, versus $1.4 million for Q4 2024 and $19.1 million for Q2 2024.